SB-215505( —— )

Catalog No. M34411 CAS No. 162100-15-4

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Get Quotation Bulk Inquiry Add to Cart

Product Name

SB-215505
Note

Research use only, not for human use.
Brief Description

SB-215505 is a subtype-selective 5-HT2B receptor antagonist that inhibits 5-HT2B, 5-HT2A, and 5-HT2C.SB-215505 can be used to study prostate cancer.
Description

SB-215505 is a potent and subtype-selective 5-HT2B receptor antagonist with pKi values of 8.3, 6.77, 7.66 for 5-HT2B, 5-HT2A, 5-HT2C, respectively. SB-215505 increases wakefulness and motor activity in rats.
In Vitro

SB-215505 is 30 fold selective for the 5-HT2B over the 5-HT2A receptor, and only marginally selective over the 5-HT2C receptor.
In Vivo

SB-215505 (0.1-1.0 mg/kg; i.p.; two doses) dose-dependently increases wakefulness (W) and decreases IS, PS, SWS-2.Animal Model:Male Sprague-Dawley rats weighing 230-260 g Dosage:0.1, 0.3 and 1.0 mg/kg Administration:IP; two doses (4 days between two doses) Result:Dose-dependently increased wakefulness (W) and decreased intermediate stage of sleep (IS), paradoxical sleep (PS), SWS-2.
Synonyms

——
Pathway

GPCR/G Protein
Target

5-HT Receptor
Recptor

5-HT Receptor
Research Area

——
Indication

——

1. C Reavill, et al. Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist. Br J Pharmacol. 1999 Feb;126(3):572-4.?

Calculator

molnova catalog